ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RMTI vs MRK // GROSS PROFIT MARGIN

Rockwell Medical Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: RMTI 0 — MRK 9
▲ GROSS PROFIT MARGIN LEADER: MRK
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RMTI VS. MRK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RMTI MRK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE 16.90% 74.80% -57.90 MRK /gross-margins <GO>
Return on Invested Capital (ROIC) -10.60% 20.70% -31.30 MRK /roic <GO>
EV/EBITDA & P/E Valuation — 15.3x — TIE /valuation <GO>
Free Cash Flow Yield -2.24% 3.42% -5.66 MRK /fcf-yield <GO>
Operating Margin -6.80% 34.30% -41.10 MRK /operating-margins <GO>
Net Profit Margin -7.70% 28.10% -35.80 MRK /net-margins <GO>
Revenue Growth (YoY) — 1.30% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.26% -2.26 MRK /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.19 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 7/9 -4.00 MRK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.0 51.7 -10.71 MRK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.92 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 18.4x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $29.5M $361.02B -$360.99B MRK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RMTI REV MRK REV RMTI GROSS % MRK GROSS % RMTI FCF MRK FCF
FY 2025 $69.3M $65.01B 16.9% 74.8% -$659.0K $12.36B
FY 2024 $101.5M $64.17B 17.2% 76.3% $4.2M $18.10B
FY 2023 $0 $60.12B — — -$9.4M $10.30B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RMTI // BETA —
MRK // BETA 0.92